BTAI vs MS · rev $388.0K vs P/E 20, rev $41.93B
BioXcel Therapeutics Inc (BTAI) versus Morgan Stanley (MS) — a side-by-side from cached financials, not a winner call.
BioXcel Therapeutics Inc (BTAI) is a drug manufacturers - specialty & generic company listed on US.
Morgan Stanley (MS) is a capital markets company listed on US. It is led by Ted Pick.
Latest reported BTAI revenue for 2026-06-30 was $388.0K. Net income was -$27.4M. Revenue was up 88.3% from 2026-03-31 to 2026-06-30. BTAI currently screens at market cap $36.1M.
Latest reported MS revenue for 2026-06-30 was $41.93B. Net income was $11.15B. MS currently screens at market cap $344.27B and trailing P/E 19.8.
BTAI currently screens at market cap $36.1M. MS currently screens at market cap $344.27B and trailing P/E 19.8.
Not investment advice. Open the BTAI and MS stock pages for the full models.
Not investment advice.